Fujirebio Diagnostics CA 19-9
This article was originally published in The Gray Sheet
Executive Summary
First blood test for monitoring pancreatic cancer gains FDA market clearance, announced May 13. The laboratory radioimmunoassay accurately tracks response to chemotherapy treatment and disease status, the Malvern, Pennsylvania company claims. The assay will be distributed exclusively by Polymedco...